EB 001

Drug Profile

EB 001

Alternative Names: EB-001

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Bonti
  • Class Bacterial proteins; Bacterial toxins
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glabellar lines

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Glabellar lines in USA (IM) (NCT02939326)
  • 25 Oct 2016 Bonti plans a phase II trial for Glabellar lines in USA (NCT02939326)
  • 11 Oct 2016 Preclinical trials in Glabellar lines in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top